Illustrating the safety of a new drug treatment designed for spinal cord injury

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants.

New research supports potential link between low-level lead exposure and liver injury

Nearly a decade on, the Flint water crisis still looms large in the minds of environmental toxin researchers. It was — and continues to be

November 27, 2023

FDA is poised to pull Ocaliva as adcomm documents question post-approval study results

The FDA appeared ready to pull its accelerated approval of Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, bluntly laying out its rationale in

September 12, 2024

The Crucial Role of Patient-Level Data in Elevating Healthcare Outcomes

Kamya Elawadhi, Chief Client Officer, Doceree In today’s healthcare landscape, patients are more informed than ever before, thanks to easy access to online resources and

July 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.